Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan Stein

Blood (2022) 140 (Supplement 1): 3333–3335.

https://doi.org/10.1182/blood-2022-156564

Published: 2022

Journal Articles

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Koichi Takahashi, Anna Jonasova, Selina M. Luger, Aref Al-Kali, David Valcarcel, Erica D. Warlick, Maria Diez-Campelo, Michael K Keng, Feng Wang, Ken Furudate, Patrick S. Zbyszewski, Matthew Parris, Steven M. Fruchtman, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2021-152048

Published: 2021

Journal Articles

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Blood (2021) 138 (Supplement 1): 261.

https://doi.org/10.1182/blood-2021-145008

Published: 2021

Journal Articles

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Blood (2021) 138 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2021-147569

Published: 2021

Journal Articles

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan G Holtan, MD, Claudio G. Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136479

Published: 2020

Journal Articles

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Rose Wangen, Dixie Lewis, RN,BA, JoAnn Knox, Martin Schroeder, Martin Felices, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136398

Published: 2020

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Blood (2020) 136 (Supplement 1): 44–46.

https://doi.org/10.1182/blood-2020-136337

Published: 2020

Journal Articles

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan Holtan, MD, Claudio G Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2019) 134 (Supplement_1): 2009.

https://doi.org/10.1182/blood-2019-123421

Published: 2019

Journal Articles

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Bhaskar Kolla, MBBS, Nurul Aidah Abdul Halim, MBBS, Zohar Sachs, MD PhD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Fiona He, MD, Lao Zhentang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 3432.

https://doi.org/10.1182/blood-2019-123306

Published: 2019

Journal Articles

Predicted Leukocyte Telomere Length and Risk of Myeloid Neoplasms

Jenny Poynter, PhD, Spencer Kelley, Marina Marcato, Erica Langer, Anthony J Hooten, Mary Rachel Stimson, Michelle A. Roesler, BS, Phuong L. Nguyen, MD, Adina Cioc, MD, Erica D. Warlick, MD, Nathan Pankratz

Blood (2019) 134 (Supplement_1): 1335.

https://doi.org/10.1182/blood-2019-131224

Published: 2019

Journal Articles

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Michelle A. Roesler, BS, Amy Linabery, PhD MS, Michaela Richardson, MPH, Adina Cioc, MD, Betsy A Hirsch, PhD, Phuong L. Nguyen, MD, Erica D. Warlick, MD, Jenny Poynter, PhD

Blood (2019) 134 (Supplement_1): 3014.

https://doi.org/10.1182/blood-2019-130940

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 777.

https://doi.org/10.1182/blood-2019-130476

Published: 2019

Journal Articles

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Nelli Bejanyan, MD, Mei-Jie Zhang, PhD, Khalid Bo-Subait, Hai-Lin Wang, MPH, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Brenda M Sandmaier, MD, Mark Litzow, MD, Partow Kebriaei, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 4603.

https://doi.org/10.1182/blood-2019-123513

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Michael K Keng, MD, Samer K. Khaled, MD, Brenda Cooper, MD, Erica D. Warlick, MD, David Ramies, MD, Silvia Mappa, MD, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2018-99-112741

Published: 2018

Journal Articles

Factors Predicting Early Mortality in Newly Diagnosed Myelodysplastic Syndrome (MDS): A Population Based Study

Annie M. Jacobsen, MD, Jenny Poynter, PhD, Michaela Richardson, MPH, Phuong L. Nguyen, MD, Betsy A Hirsch, PhD, Adina Cioc, MD, Michelle A. Roesler, BS, Erica D. Warlick, MD

Blood (2018) 132 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2018-99-112319

Published: 2018

Journal Articles

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

Margaret L. MacMillan, MD, Keli Lee Hippen, PhD, David H. McKenna, MD, Todd E. DeFor, MS, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Jeffrey S. Miller, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, John E. Wagner, MD

Blood (2018) 132 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2018-99-113100

Published: 2018

Journal Articles

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Tara L. Lin, MD, Geoffrey L. Uy, MD, Matthew J. Wieduwilt, Laura F. Newell, MD, Robert K. Stuart, MD, Bruno C Medeiros, MD, Gary J. Schiller, Eric Rubenstein, MD, Wendy Stock, MD, Erica D. Warlick, MD, Matthew Foster, Dale L. Bixby, Nikolai A. Podoltsev, MD PhD, Qi An, Stefan Faderl, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 1698.

https://doi.org/10.1182/blood.V130.Suppl_1.1698.1698

Published: 2017

NARROW

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Predicted Leukocyte Telomere Length and Risk of Myeloid Neoplasms

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Factors Predicting Early Mortality in Newly Diagnosed Myelodysplastic Syndrome (MDS): A Population Based Study

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only